ST
UTHR icon

Spot Trading’s United Therapeutics UTHR Stock Holding History

Spot Trading’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$1.3M Buy
+11,100
New +$1.42M 0.02% 981
2017
Q2 		– Sell
-10,700
Closed -$1.45M – 3456
2017
Q1 		$1.45M Buy
10,700
+9,800
+1,089% +$1.48M 0.05% 518
2016
Q4 		$129K Sell
900
-800
-47% -$102K ﹤0.01% 2110
2016
Q3 		$201K Buy
1,700
+800
+89% +$96.1K ﹤0.01% 2086
2016
Q2 		$95K Sell
900
-200
-18% -$22.3K ﹤0.01% 2549
2016
Q1 		$123K Buy
1,100
+200
+22% +$25.3K ﹤0.01% 2476
2015
Q4 		$141K Buy
+900
New +$131K ﹤0.01% 2661
2014
Q1 		– Sell
-6,300
Closed -$712K – 4520
2013
Q4 		$712K Buy
6,300
+2,700
+75% +$243K ﹤0.01% 2217
2013
Q3 		$284K Buy
3,600
+1,200
+50% +$87.7K ﹤0.01% 2787
2013
Q2 		$158K Buy
+2,400
New +$155K ﹤0.01% 3217

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Spot Trading's UTHR Position: Q3 2017 in Review

Spot Trading sold out of United Therapeutics (UTHR) in Q3 2017, closing a stake of 3,489 shares — an estimated $446K sold.

Spot Trading first reported a position in UTHR in Q2 2013 and held it in 10 quarters. The position peaked at $453K in Q2 2017. 373 funds tracked by Wall St. Rank hold UTHR as of Q3 2017.

  • Spot Trading reported no remaining United Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Spot Trading sold 3,489 United Therapeutics shares in Q3 2017, an estimated $446K.
  • Spot Trading first reported a position in United Therapeutics in Q2 2013 and held it in 10 quarters.
  • Spot Trading's United Therapeutics position peaked at $453K in Q2 2017.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2017.

Based on Spot Trading's 13F filing for Q3 2017, filed 6 Nov 2017.